Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report)'s share price hit a new 52-week low on Monday . The company traded as low as $9.92 and last traded at $10.15, with a volume of 451980 shares traded. The stock had previously closed at $10.38.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on ROIV shares. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.
Get Our Latest Report on Roivant Sciences
Roivant Sciences Price Performance
The firm has a fifty day simple moving average of $10.65 and a 200-day simple moving average of $11.35. The firm has a market cap of $6.75 billion, a P/E ratio of -63.06 and a beta of 1.26.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Insider Activity
In related news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction dated Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,395,541 shares of company stock worth $15,028,538 over the last three months. 7.90% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Roivant Sciences
A number of institutional investors and hedge funds have recently bought and sold shares of ROIV. Nordea Investment Management AB raised its holdings in shares of Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company's stock valued at $3,306,000 after purchasing an additional 52,031 shares during the last quarter. Barclays PLC boosted its holdings in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Retirement Systems of Alabama grew its position in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after purchasing an additional 112,286 shares in the last quarter. Elevate Capital Advisors LLC purchased a new stake in Roivant Sciences in the 4th quarter valued at about $2,116,000. Finally, State Street Corp lifted its position in shares of Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company's stock worth $225,737,000 after buying an additional 1,118,561 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
